China Universal Asset Management Co. Ltd. grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 10.4% ...
Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback